The U.S. Department of Health and Human Services (HHS) said McKesson Corp. will be the central distributor for future coronavirus vaccines, sending the U.S. drug distributor’s shares up more than 3%.
If you are not happy with the results below please do another search
50 search results for:
Novavax entered into an agreement to provide the United Kingdom with 60 million doses of the company’s Covid-19 vaccine candidate should NVX-CoV2373 be approved, as well as a late-stage efficacy study in the U.K.
The United States is tying payments for Covid-19 vaccines to timing milestones for production and approval, according to public documents and a Trump administration official, putting pressure on drugmakers including Moderna Inc. to meet ambitious targets.
Less than one month after GlaxoSmithKline took a 10% stake in CureVac, the Germany-based company raised $213 million in an initial public offering.
Austin, Texas-based TFF Pharmaceuticals inked a worldwide exclusive licensing deal with Hellerup, Denmark’s Union Therapeutics for the use of TFF’s Thin Film Freezing technology in combination with niclosamide for Covid-19 treatments.
The U.S. Food and Drug Administration granted accelerated approval for NS Pharma’s Viltepso (viltolarsen) injection for patients with Duchenne muscular dystrophy who are amenable to exon 53 skipping therapy.
U.S. government scientists started efforts to manufacture a strain of the novel coronavirus that could be used in human challenge trials of vaccines, a controversial type of study in which healthy volunteers would be vaccinated and then intentionally infected with the virus, Reuters learned.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
North Dakota, Wyoming and Alabama are the latest U.S. states launching apps to warn users about potential exposure to the novel coronavirus by tracking their encounters, representatives for the states told Reuters.
(Reuters) – Any potential COVID-19 vaccine backed by the Trump administration’s “Operation Warp Speed” program is unlikely to receive a green light from regulators any earlier than November or December, given the time needed for a large-scale clinical trial, the National Institutes of Health director said on Thursday. In a call with reporters, Francis Collins […]